ANXA6 and pancreatic ductal adenocarcinoma: ANXA6-EVs, derived from cancer-associated stromal fibroblasts (CAF), promotes tumor cell invasiveness in pancreatic ductal adenocarcinoma, and the blockade of CD9 impairs the uptake of ANXA6-EVs by pancreatic ductal adenocarcinoma cells [28, 71].